Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers
Open Access
- 22 April 2022
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (2), 487-497
- https://doi.org/10.1002/alz.12674
Abstract
Introduction It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods Cross-sectional and longitudinal data from the multicenter, memory clinic-based DELCODE study. Results The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD-A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO-A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.Keywords
This publication has 34 references indexed in Scilit:
- Prevalence of Cerebral Amyloid Pathology in Persons Without DementiaJAMA, 2015
- A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRINeuroImage, 2015
- Subjective Cognitive Impairment Subjects in Our Clinical PracticeDementia and Geriatric Cognitive Disorders Extra, 2014
- A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseAlzheimer's & Dementia, 2014
- The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?Alzheimer's & Dementia, 2014
- Misuse of the Linear Mixed Model When Evaluating Risk Factors of Cognitive DeclineAmerican Journal of Epidemiology, 2011
- Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic studyThe Lancet Neurology, 2011
- Mild cognitive impairment as a diagnostic entityJournal of Internal Medicine, 2004
- Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human BrainNeuron, 2002
- A new family of power transformations to improve normality or symmetryBiometrika, 2000